title: Pharmacotherapy response and regional cerebral blood flow characteristics in patients with obsessive-compulsive disorder.
abstract: OBJECTIVE
  To analyze the correlation between the pharmacotherapy response and the characteristics of the pre-treatment regional cerebral blood flow (rCBF) in patients with obsessive-compulsive disorder (OCD).
  
  
  METHODS
  Single-photon emission-computed tomography (SPECT) was used to determine the pre-treatment rCBF in 30 OCD patients and 30 normal controls. Based on their clinical remission response, the subjects were divided into two groups: selective serotonin reuptake inhibitors (SSRIs) and SSRIs plus quetiapine. The subjects with clinical remission response were identified after treatment for a period of 24 weeks, and the rCBF imaging data were processed using statistical parametric mapping (SPM) software with two-sample Z-tests.
  
  
  RESULTS
  Nineteen OCD patients who achieved clinical remission were included in the study. Increased rCBF in forebrain regions, including the frontal lobe, cingulate gyrus, hypothalamus, and basal ganglia, was found in 11 responders to SSRIs compared to normal control patients. The eight SSRI plus quetiapine responders exhibited a decrease in rCBF within posterior brain regions, including the parietal lobe, cerebellar vermis, and occipital lobe, and an increase in rCBF in the frontal lobe, thalamus, basal ganglia, and cerebellum tonsil compared to normal control patients.
  
  
  CONCLUSIONS
  The characteristics of increased rCBF in forebrain regions and decreased rCBF in posterior brain regions before treatment of OCD patients was a potentially predictor of treatment response to guide treatment options.
authors.forename: Sheng-Lin
authors.initials: SL
authors.lastname: Wen
authors.forename: Mu-Hua
authors.initials: MH
authors.lastname: Cheng
authors.forename: Min-Feng
authors.initials: MF
authors.lastname: Cheng
authors.forename: Ji-Hui
authors.initials: JH
authors.lastname: Yue
authors.forename: Hong
authors.initials: H
authors.lastname: Wang
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001921:Brain / Q000098:blood supply* / Q000187:drug effects*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D003987:Dibenzothiazepines / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D059907:Functional Neuroimaging; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D000069348:Quetiapine Fumarate; D012074:Remission Induction; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015899:Tomography, Emission-Computed, Single-Photon; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate; D017367:Selective Serotonin Reuptake Inhibitors
references.citation: Psychiatry Res. 2003 Oct 30;124(2):87-103
references.pmid: 14561427
references.citation: Psychiatry Res. 2005 Feb 28;138(2):89-97
references.pmid: 15766633
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):85-102
references.pmid: 12551730
references.citation: Neuropsychopharmacology. 2002 Nov;27(5):782-91
references.pmid: 12431852
references.citation: Acta Psychiatr Scand. 2003 Apr;107(4):291-7
references.pmid: 12662252
references.citation: Psychiatry Res. 2000 Jul 10;99(1):15-27
references.pmid: 10891646
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2006 May;30(3):400-12
references.pmid: 16503369
references.citation: Psychiatry Res. 2003 Jun 30;123(2):125-34
references.pmid: 12850251
references.citation: J Am Acad Child Adolesc Psychiatry. 2001 Aug;40(8):895-902
references.pmid: 11501688
references.citation: Semin Clin Neuropsychiatry. 2001 Apr;6(2):82-101
references.pmid: 11296309
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jun;30(4):737-40
references.pmid: 16431007
references.citation: Science. 2008 Jul 18;321(5887):421-2
references.pmid: 18635808
references.citation: J Affect Disord. 2012 May;138(3):313-21
references.pmid: 22331021
references.citation: Mol Psychiatry. 2006 Jul;11(7):622-32
references.pmid: 16585942
references.citation: J Clin Psychiatry. 2004 Apr;65(4):565-8
references.pmid: 15119922
references.citation: Neuropsychopharmacology. 1999 Dec;21(6):683-93
references.pmid: 10633474
references.citation: Aust N Z J Psychiatry. 2007 Feb;41(2):129-35
references.pmid: 17464690
references.citation: Psychother Psychosom. 2005;74(5):269-76
references.pmid: 16088264
references.citation: Psychiatry Res. 2007 Jan 15;154(1):85-92
references.pmid: 17208418
references.citation: Arch Gen Psychiatry. 2000 Aug;57(8):794-801
references.pmid: 10920469
references.citation: Arch Gen Psychiatry. 2002 Mar;59(3):250-61
references.pmid: 11879163
references.citation: Psychiatry Res. 2008 Aug 30;163(3):236-47
references.pmid: 18667293
references.citation: J Psychiatry Neurosci. 2008 Sep;33(5):405-12
references.pmid: 18787662
references.citation: Neuropsychobiology. 2006;53(3):157-68
references.pmid: 16707915
references.citation: Psychiatr Clin North Am. 2000 Sep;23(3):563-86
references.pmid: 10986728